Fierce Biotech · Jul 27, 2026
FDA approves Freenome colorectal cancer blood test to be marketed by Abbott
The FDA has approved Freenome’s new blood-based colorectal cancer test, SimpleScreen CRC, which Abbott will exclusively market in the U.S.
Latest medical news · page 35
The latest headlines across every section, pulled from official and open-access sources.
Fierce Biotech · Jul 27, 2026
InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test
InnoCare Pharma announced Monday that its oral tyrosine kinase 2 (TYK2) inhibitor fadeucravacitinib met the primary endpoint in a phase 3 trial of adults with moderate-to-severe plaque psoriasis.
Fierce Biotech · Jul 27, 2026
After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaboration
After signing a deal worth up to $486 million with Italian biopharma Chiesi to develop its pulmonary arterial hypertension (PAH) candidate seralutinib in 2024, Gossamer Bio has ended the collaboration and licensing agreement.
Fierce Biotech · Jul 27, 2026
Legend Biotech CEO abruptly steps down without permanent replacement
In a sudden leadership shift, Legend Biotech announced that its CEO, Ying Huang, Ph.D., resigned on Friday, with no permanent replacement yet named.
KFF Health News · Jul 27, 2026
Tracking State Rural Health Transformation Plans
KFF Health News is working to collect and post approved plans as more states respond to emails and public records requests for their documents.
KFF Health News · Jul 27, 2026
Trump Administration Demands Hospitals Share Emergency Room Records
The tiny federal agency that tracks consumer product safety is pressuring hospitals to turn over patient records from emergency room visits, including about injuries that have nothing to do with consumer products.
DHSC (UK) · Jul 27, 2026
Transparency data: DHSC: workforce management information June 2026
Reports on departmental staff numbers and costs.
Fierce Biotech · Jul 27, 2026
Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug
Argenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease drug.
Fierce Biotech · Jul 27, 2026
AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates
AstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of ADCs despite scrapping two candidates that underperformed in the clinic.
CDC Emerging Infections · Jul 27, 2026
A Multi-Partner Effort to Launch and Sustain Wastewater Surveillance, United States
J. Yoder et al.
CDC Emerging Infections · Jul 27, 2026
Emergence of Rabies in Cape Fur Seals, South Africa
C. Ngoepe et al.
Fierce Biotech · Jul 27, 2026
Labcorp launches DTC ‘Genetic Health Panel’ to seek out multiple diseases
Labcorp is launching the Marker by Labcorp Genetic Health Panel, a new direct-to-consumer genetic testing tool that analyzes 163 genes to determine patients’ risk of over 100 hereditary health conditions.
JAMA Network Open · Jul 27, 2026
Financial Stressors as Proximal Risk Indicators for Suicide
Psychiatry
JAMA Network Open · Jul 27, 2026
A Call to Center the Individual in Cardiovascular Prevention
Health Policy
JAMA Network Open · Jul 27, 2026
Tobacco Smoking Cessation and Cancer Stage
This cross-sectional study uses data from the National Cancer Database to examine the association between tobacco smoking cessation and cancer stage among US adults.
JAMA Network Open · Jul 27, 2026
Surveillance Outcomes After Template-Guided Mapping Biopsy for Prostate Cancer
This cohort study assesses long-term oncologic and quality-of-life outcomes after transperineal template-guided mapping biopsy in patients with prostate cancer.
JAMA Network Open · Jul 27, 2026
Financial Stressors and Suicide
This case-control study examines whether financial stressors in the year before death are associated with suicide risk among US veterans.
JAMA Network Open · Jul 27, 2026
Cost-Effectiveness of Surveillance After Chemoradiotherapy for Esophageal Cancer
This secondary analysis of a randomized clinical trial assesses the cost-effectiveness of active surveillance compared with standard surgery among patients with esophageal cancer who achieved a complete clinical response after neoadjuvant chemoradiotherapy.
JAMA Network Open · Jul 27, 2026
Restrictive vs Liberal Transfusion Strategy After Myocardial Infarction
This post hoc analysis of the MINT randomized clinical trial estimates bayesian posterior risk differences and posterior probabilities that a liberal vs restrictive transfusion strategy is associated with reduced risk of 30-day death or myocardial infarction.
JAMA Network Open · Jul 27, 2026
Intraarterial Dexamethasone for Pain Relief After Uterine Fibroid Embolization
This randomized clinical trial assesses whether intraarterial dexamethasone administered during uterine fibroid embolization reduces postprocedural pain compared with placebo.
JAMA Network Open · Jul 27, 2026
World Health Organization Multimodal Improvement Strategy for Hand Hygiene
This stepped-wedge cluster randomized trial evaluates the effectiveness and sustainability of the World Health Organization multimodal improvement strategy for hand hygiene in Ugandan health care facilities.
JAMA Network Open · Jul 27, 2026
Antipsychotic Exposure and Pharmacologically Treated Type 2 Diabetes in Dutch Youths
This cohort study examines the association between initiation of antipsychotic medication and annual prevalence of pharmacologically treated type 2 diabetes among youths in the Netherlands.
JAMA Network Open · Jul 27, 2026
Cardiovascular Risk Factor Prevalence and Control by Education Strata
This secondary analysis of a cross-sectional study of older adults examines cardiovascular disease risk factor trends in the US, England, and South Korea.
MedCity News · Jul 26, 2026
Crystalys Therapeutics Tacks On $130M for Pivotal Tests of Gout Drug
Crystalys’s dotinurad is currently in pivotal testing for gout, a prevalent inflammatory disorder with few treatment options. The drug has the same mechanism of action as a molecule that Sobi added to its pipeline through a $950 million acquisition. The post Crystalys Therapeutics Tacks On $130M for Pivotal Tests of Gout Drug appeared first on MedCity News .